Abstract
The transcription of antioxidant response element (ARE)-containing cytoprotective genes has been proposed as a means to combat oxidative stress-related disorders, such as cancer and Parkinsons disease. Transactivation of the ARE requires the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). Cellular levels of Nrf2 protein are regulated by the Kelch-like ECH-associated protein 1 (Keap1), a substrate adaptor protein for the ubiquitin ligase machinery and subsequent proteasomal degradation. Recently, detailed studies have elucidated the structure and interactions of the Keap1-containing ubiquitin ligase complex. Here, we propose that small molecule modulation of Keap1 protein:protein interactions may permit Nrf2s nuclear accumulation and the transcription of AREdependent genes to enhance cellular resistance to oxidative insult.
Keywords: Keap1, Nrf2, Cul3, antioxidant, oxidative stress, antioxidant response element
Current Topics in Medicinal Chemistry
Title: Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Volume: 7 Issue: 10
Author(s): Jonathan T. Kern, Mark Hannink and J. Fred Hess
Affiliation:
Keywords: Keap1, Nrf2, Cul3, antioxidant, oxidative stress, antioxidant response element
Abstract: The transcription of antioxidant response element (ARE)-containing cytoprotective genes has been proposed as a means to combat oxidative stress-related disorders, such as cancer and Parkinsons disease. Transactivation of the ARE requires the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). Cellular levels of Nrf2 protein are regulated by the Kelch-like ECH-associated protein 1 (Keap1), a substrate adaptor protein for the ubiquitin ligase machinery and subsequent proteasomal degradation. Recently, detailed studies have elucidated the structure and interactions of the Keap1-containing ubiquitin ligase complex. Here, we propose that small molecule modulation of Keap1 protein:protein interactions may permit Nrf2s nuclear accumulation and the transcription of AREdependent genes to enhance cellular resistance to oxidative insult.
Export Options
About this article
Cite this article as:
Kern T. Jonathan, Hannink Mark and Fred Hess J., Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy, Current Topics in Medicinal Chemistry 2007; 7 (10) . https://dx.doi.org/10.2174/156802607780906825
DOI https://dx.doi.org/10.2174/156802607780906825 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics
Current Molecular Medicine Conference Report: 9th International Summer School of Neurology
CNS & Neurological Disorders - Drug Targets N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Subject Index to Volume 10
Current Pharmaceutical Design Antipsychotic Medication: The Potential Role of 5-HT1A Receptor Agonism
Current Pharmaceutical Design Sleep in Interstitial Lung Disease
Current Respiratory Medicine Reviews Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors
CNS & Neurological Disorders - Drug Targets Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology An Overview of Pharmacogenetics in Psychotropic Drugs
Current Psychiatry Reviews 5-HT2 Receptors
Current Drug Targets - CNS & Neurological Disorders A Review of Current Strategies for Treatment Resistant Obsessive-Compulsive Disorder
Current Drug Therapy Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse
Current Medicinal Chemistry - Central Nervous System Agents L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Blocking Receptor Protein Tyrosine Phosphatase β /ζ: A Potential Therapeutic Strategy for Parkinsons Disease
Current Medicinal Chemistry Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Efficacy and Adverse Effects of Venlafaxine in Children and Adolescents with ADHD: A Systematic Review of Non-controlled and Controlled Trials
Reviews on Recent Clinical Trials Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry How to Optimize the Effectiveness and Safety of Parkinson’s Disease Therapy? – A Systematic Review of Drugs Interactions with Food and Dietary Supplements
Current Neuropharmacology